Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results
Milestone Pharmaceuticals posted a wider loss but beat estimates, announced cost cuts, and saw shares fall 14.4% as analysts lowered price targets.
Follow the latest Milestone Pharmaceuticals Inc. (MIST) news and market headlines alongside the live MIST price. Stay informed on what's moving MIST.
Milestone Pharmaceuticals posted a wider loss but beat estimates, announced cost cuts, and saw shares fall 14.4% as analysts lowered price targets.
TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.
Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.
Key elements of the cost-efficiency measures include:Bringing the sales force in-house: the Company plans to retain the existing field sales team of approximately 45 dedicated representatives, transitioning them from a
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 50 percent decrease over losses of $(0.12) per
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to MIST, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.